Technical Analysis for SPPI - Spectrum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 9.53 -0.94% -0.09
SPPI closed down 0.94 percent on Thursday, April 18, 2019, on 78 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical SPPI trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Multiple of Ten Bearish Other -0.94%
Lower Bollinger Band Touch Weakness -0.94%
Oversold Stochastic Weakness -0.94%
Narrow Range Bar Range Contraction -4.51%
NR7 Range Contraction -4.51%
Stochastic Reached Oversold Weakness -4.51%
Multiple of Ten Bearish Other -4.51%
Inside Day Range Contraction -4.51%

Older signals for SPPI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Spectrum Pharmaceuticals, Inc., a biotechnology company, engages in acquiring, developing, and commercializing prescription drug products primarily in the areas of hematology and oncology. The company's oncology products include FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy, and to diminish toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; and ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody. It also develops apaziquone that is under Phase III clinical trial for non-muscle invasive bladder cancer; and belinostat, which is under Phase II registrational trial for the various hematological and solid tumors. In addition, the company develops ozarelix that is under randomized phase II clinical trial in prostate cancer patients; ortataxel, which has completed Phase II studies in solid tumor patients; lucanthone, an orally administered small-molecule that has completed preclinical tests; SPI-1620, which has completed Phase I study is a peptide agonist of endothelin B receptors; RenaZorb, a second-generation lanthanum-based nanoparticle phosphate binding agent; and SPI-2012, a drug for the treatment of chemotherapy induced neutropenia. It has strategic collaborations with Allergan, Inc., Nippon Kayaku Co. Ltd., and Handok Pharmaceuticals Co. Ltd. for the development and commercialization of apaziquone; and TopoTarget A/S for the development and commercialization of belinostat. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.
Medicine Biotechnology Health Cancer Chemotherapy Radiation Prostate Cancer Solid Tumor Osteosarcoma Cancer Therapy Non Muscle Invasive Bladder Cancer Oncology Products Treating Cancer Neutropenia Ozarelix
Is SPPI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 25.29
52 Week Low 6.22
Average Volume 922,125
200-Day Moving Average 14.722
50-Day Moving Average 10.6738
20-Day Moving Average 10.372
10-Day Moving Average 10.288
Average True Range 0.5421
ADX 20.15
+DI 13.1004
-DI 29.123
Chandelier Exit (Long, 3 ATRs ) 9.7337
Chandelier Exit (Short, 3 ATRs ) 10.9563
Upper Bollinger Band 11.4276
Lower Bollinger Band 9.3164
Percent B (%b) 0.1
BandWidth 20.354801
MACD Line -0.2021
MACD Signal Line -0.086
MACD Histogram -0.1161
Fundamentals Value
Market Cap 750.82 Million
Num Shares 78.8 Million
EPS -1.00
Price-to-Earnings (P/E) Ratio -9.53
Price-to-Sales 11.56
Price-to-Book 7.68
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.04
Resistance 3 (R3) 10.03 9.85 9.95
Resistance 2 (R2) 9.85 9.72 9.86 9.92
Resistance 1 (R1) 9.69 9.64 9.60 9.70 9.89
Pivot Point 9.52 9.52 9.47 9.52 9.52
Support 1 (S1) 9.35 9.39 9.27 9.36 9.17
Support 2 (S2) 9.18 9.31 9.18 9.14
Support 3 (S3) 9.02 9.18 9.11
Support 4 (S4) 9.02